Alice Agliano

Alice Agliano

Auto-generated profile, based on publicly available information

Alice Agliano

Department of Materials Department of Bioengineering Institute of Biomedical Engineering Imperial College London London SW7 2AZ UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Seminars in Cancer Biology
Verified
Journal Article
Open access
AAAlice Agliano
Alice Agliano
ACAlfonso Calvo
Alfonso Calvo
CBCarol Box
Carol Box
Despite a continuing debate about the existence of cancer stem cells (CSCs), recent discoveries have provided further support for their existence and their roles in drug resistance, cancer recurrence and metastasis. CSC characteristics, such as self-renewal and tumour initiation, and supporting cellular processes, particularly the epithelial-to-mesenchymal transition, are attracting a great deal of attention from cancer researchers as they offer opportunities for discovering novel therapeutic targets for future drug development. However, the identification of potential CSC targets presents clear obstacles due to a lack of truly specific CSC markers and the reality of CSC plasticity, making this task a significant challenge. Agents that target developmental signalling pathways, such as Notch, Wnt and Hedgehog, are now in clinical trials whilst alternative approaches including immune-based therapies and microRNA-mediated pathway inhibitors are producing promising pre-clinical results. Here, we discuss the contribution of CSCs to cancer metastasis and the scope of opportunities for therapeutic intervention. In particular, we consider CSC-targeting agents for which there is experimental evidence of anti-metastatic properties and which may have potential to eventually limit relapse and impede metastasis in patients.

2 April 2023 in Advanced Materials
Verified
Journal Article
Open access
ACAdam Creamer
Adam Creamer
AFAlessandra Lo Fiego
Alessandra Lo Fiego
AAAlice Agliano
Alice Agliano
LPLino Prados‐Martin
Lino Prados‐Martin
HHHåkon Høgset
Håkon Høgset
MSMolly M. Stevens
Molly M. Stevens
Semiconducting polymer nanoparticles (SPNs) are explored for applications in cancer theranostics because of their high absorption coefficients, photostability, and biocompatibility. However, SPNs are susceptible to aggregation and protein fouling in physiological conditions, which can be detrimental for in vivo applications. Here, a method for achieving colloidally stable and low‐fouling SPNs is described by grafting poly(ethylene glycol) (PEG) onto the backbone of the fluorescent semiconducting polymer, poly(9,9′‐dioctylfluorene‐5‐fluoro‐2,1,3‐benzothiadiazole), in a simple one‐step substitution reaction, postpolymerization. Further, by utilizing azide‐functionalized PEG, anti‐human epidermal growth factor receptor 2 (HER2) antibodies, antibody fragments, or affibodies are site‐specifically “clicked” onto the SPN surface, which allows the functionalized SPNs to specifically target HER2‐positive cancer cells. In vivo, the PEGylated SPNs are found to have excellent circulation efficiencies in zebrafish embryos for up to seven days postinjection. SPNs functionalized with affibodies are then shown to be able to target HER2 expressing cancer cells in a zebrafish xenograft model. The covalent PEGylated SPN system described herein shows great potential for cancer theranostics.

1 November 2012 in Neoplasia
Verified
Journal Article
Open access
IMInes Martin-Padura
Ines Martin-Padura
PMPaola Marighetti
Paola Marighetti
GGGiuliana Gregato
Giuliana Gregato
AAAlice Agliano
Alice Agliano
OMOmar Malazzi
Omar Malazzi
Francesco BertoliniFrancesco Bertolini
Francesco Bertolini
Cell fusion plays a well-recognized physiological role during development, while its function during progression is still unclear. Here, we show that acute myeloid leukemia (AML) cells spontaneously fused with murine host cells in vivo. AML cells fused in most cases with mouse macrophages. Other targets of AML cell fusion were dendritic and endothelial cells. Cytogenetic and molecular analysis revealed that successive recipients conserved detectable amounts of parental DNA. Moreover, in a mouse AML1-ETO model where female AML1-ETO-leukemic cells, expressing CD45.2, were injected in congenic CD45.1 male mice AML cells, we found hybrid cells expressing both allelic types of CD45 and XXY set of sexual chromosomes. More importantly, the fusion protein AML1-ETO was transferred in the hybrid cells. When sorted hybrid cells were reinjected in a secondary recipient, they gave rise to leukemia with 100% penetrance and similar time of onset of leukemic cells. Our data indicate that in vivo fusion of cancer cells with host cells may be a mechanism of gene transfer for cancer dissemination and suggest that fused cells may be used to identify still unrecognized leukemogenic genes that are conserved in hybrid cells and able to perpetuate leukemia in vivo.

13 December 2018 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
VUVéronica Uribe‐Etxebarria
Véronica Uribe‐Etxebarria
AAAlice Agliano
Alice Agliano
FUFernando Unda
Fernando Unda
Gaskon IbarretxeGaskon Ibarretxe
Gaskon Ibarretxe
Human dental pulp stem cells (DPSCs) can differentiate to a wide range of different cell lineages, and share some gene expression and functional similarities with pluripotent stem cells. The stemness of DPSCs can also be pharmacologically enhanced by the activation of canonical Wnt signaling. Here, we examined the metabolic profile of DPSCs during reprogramming linked to Wnt activation, by a short (48 hr) exposure to either the GSK3‐β inhibitor BIO (6‐bromoindirubin‐3´‐oxine) or human recombinant protein WNT‐3A. Both treatments largely increased glucose consumption, and induced a gene overexpression of pyruvate and mitochondrial acetyl‐coA producing enzymes, thus activating mitochondrial tricarboxylic acid cycle (TCA) metabolism in DPSCs. This ultimately led to an accumulation of reducing power and a mitochondrial hyperpolarization in DPSCs. Interestingly, Nile Red staining showed that lipid fuel reserves were being stored in Wnt‐activated DPSCs. We associate this metabolic reprogramming with an energy‐priming state allowing DPSCs to better respond to subsequent high demands of energy and biosynthesis metabolites for cellular growth. These results show that enhancement of the stemness of DPSCs by Wnt activation comes along with a profound metabolic remodeling, which is distinctly characterized by a crucial participation of mitochondrial metabolism.

15 April 2010
Verified
Conference Paper
Closed access
PNPaul Nguewa
Paul Nguewa
RDRoque Díaz Díaz
Roque Díaz Díaz
MRMiriam Redrado
Miriam Redrado
MCMaría Collantes
María Collantes
IPIvan Penuelas
Ivan Penuelas
ACAlfonso Calvo
Alfonso Calvo
Prostate cancer (PrCa) is the most common malignancy and the second leading cause of cancer death in men. Although localized PrCa can be successfully cured, advanced hormone refractory tumors are resistant to current therapeutic regimes. Therefore, novel approaches for effective malignancy control are still required. Molecular targeted therapies have emerged as promising alternatives to classical chemo/radiotherapy. The clinical benefit of the multi-tyrosine kinase inhibitor Sunitinib, which blocks the activity of receptors such as PDGFR, VEGFR1/2, FLT3, and c-KIT has been proven in renal carcinoma, GIST, and neuroblastoma. In this work, we have tested the therapeutical efficacy of sunitinib against PrCa both in vitro and in vivo, using the androgen-independent cell line PC-3. These cells express target receptors PDGFRa/b, and VEGFR1/2. Sunitinib dramatically reduced cell proliferation in vitro (P<0.0001) in a dose-dependent manner (with an IC50 of 1-2 micro-M) and colony formation (P<0.0001), through an autocrine mechanism. Moreover, when combined with doses of 2 and 4 Gy ionizing radiation, sunitinib enhanced the inhibitory activity of radiotherapy in colony formation assays. In vivo experiments revealed that PC3 tumor-bearing mice treated with 80 mg/Kg/day sunitinib had significantly smaller tumors (63% reduction) than controls. A single dose of 6 Gy caused tumor shrinkage by 80%, whereas the combination of both therapies resulted in more than 90% tumor reduction, suggesting that sunitinib could be used as a radiosensitizer. Positron emission tomography (PET) analyses with 18-FDG, FMISO, and FLT tracers showed a decrease in glucose uptake, hypoxia, and cell proliferation, respectively, in sunitinib-treated mice, as compared to controls. Immunohistochemical analysis for CD-31 revealed an expected reduction in tumor angiogenesis in sunitinib-treated tumors in comparison with untreated tumors. Overall, these data support the use of sunitinib as a clinically relevant drug for the treatment of PrCa. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3621.

15 April 2010 in Cancer Research
Verified
Journal Article
Closed access
IZIdoia G. Zubeldia
Idoia G. Zubeldia
CGCarmen Gil-Puig
Carmen Gil-Puig
ACAlfonso Calvo
Alfonso Calvo
LLLeyre Larzabal
Leyre Larzabal
AAAlice Agliano
Alice Agliano
JLJon Lecanda
Jon Lecanda
The liver is a major target organ for metastasis. Development of metastases requires an early release of tumour-initiating-cells from the primary tumour and adhesion of metastatic-cells into a permissive niche. We hypothesized that Epithelial-Mesenchymal Transition (EMT) underlies not only the early events, but also the promotion of the most advanced stages of a successful dissemination process to the liver. It is believed that TGFβ1 might allow tumour-initiating-cells to acquire cancer stem cell properties via EMT as a mechanism that modulates the microenvironment contributing to primary and also metastatic tumor progression. However, the mechanism of EMT induction by TGFβ1 and its involvement in liver metastases remain largely unknown. Aiming to recapitulate the hepatic metastases, we established a murine model of highly metastatic colon carcinoma cells in the context of TGFβ1-signaling. To this end, luciferase-expressing cells (MC-38luc) were pre-treated with TGFβ1 (100 pM, 48 h), before intrasplenic injection of 106 cells in C57BL/6J mice. Larger primary tumours were consistently observed and liver metastasis was achieved more rapidly after injection of MC-38luc+TGFβ1 cells, than after injection of untreated MC-38luc cells. Histological examination of liver micrometastasis also revealed slightly increased staining of Ki67, α-SMA and F4/80 markers in MC-38luc+TGFβ1 tumours. Splenic co-injection of these liver-metastatic-stem cells with non transformed hepatocytes (AML-12 cells) accelerated the incidence of liver metastasis, indicating the supportive role of the normal hepatic parenchyma. Intraperitoneal injection with a novel TGFβ1-inhibitory peptide P17 (obtained from a peptide library binding to TGFβ1) resulted in reduced liver metastasis and decrease of both CECs and CEPs. We isolated liver-metastatic cells that showed higher cellular proliferation as compared to the parental counterparts. These cells posses increased tumorogenicity in vivo, a complete lack of E-cadherin expression, and increased TGFβ1/EMT signalling properties that all relate to stem cell features. Our results provide an insight into the molecular events leading to TGFβ1-mediated malignant progression and indicate that targeting TGFβ1/EMT might represent an optimal therapeutic strategy by impairing tumor growth, stemness and further liver metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2304.